http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business News
-
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business News
-
Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
-
Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
-
Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
-
Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
-
Rubius Therapeutics (RUBY) Presents Preclinical Data for RTX-224
-
Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual Meeting
-
Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual Meeting
-
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
-
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
-
Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
-
Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
-
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
-
Rubius Therapeutics (RUBY) Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
-
Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
-
Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
-
Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
-
Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
-
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
-
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
-
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
-
Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Rubius Therapeutics (RUBY) Appoints Dannielle Appelhans as Chief Operating Officer
-
Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
-
Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
-
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
-
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
-
Rubius Therapeutics (RUBY) Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
-
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
-
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
-
Rubius Therapeutics (RUBY) Doses First Patient with RTX-240 in Combination with KEYTRUDA in Phase 1/2 Study
-
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
-
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
-
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
-
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
-
Rubius Therapeutics (RUBY) to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
-
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
-
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
-
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
-
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
-
Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
-
Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
-
Rubius Therapeutics to Announce First Quarter 2021 Financial Results
-
Rubius Therapeutics to Announce First Quarter 2021 Financial Results
-
Rubius Therapeutics (RUBY) Reports First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
-
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
